Samosa, jalebis, other Indian popular snacks to soon carry health warnings, says Health Ministry
The campaign is being rolled out first in Nagpur, where the All-India Institute of Medical Sciences (AIIMS) will serve as the pilot location for the initiative. The direction by the Ministry notes that cafeterias and public eating spaces on the campus will display easy-to-read warning boards next to food counters.
'AIIMS, Nagpur will now see the calorie count poster beside popular food stalls with clear information about sugar, fat, and trans-fat content. It will outline long-term health risks from frequent consumption. These warnings are designed to be direct and create awareness. The goal is to promote moderation, not restriction. The campaign is expected to expand to other cities later this year and we hope that this step will encourage people to make more mindful food choices,'' said a senior health official.
Encouraging healthy choices
Health Secretary Punya Salila Srivastava recently issued a direction to departments and agencies under various Ministries, instructing them to install oil and sugar board displays in the form of digital or static posters in common areas such as cafeterias, lobbies, and meeting rooms, to raise awareness on harmful consumption. They will print health messages on all official stationery and publications to reinforce daily reminders on fighting obesity as well.
They were also asked to promote healthy meals and physical activity in their offices by providing nutritious, healthier food options — including more fruits, vegetables, and low-fat options, while limiting the availability of sugary drinks and high-fat snacks — and starting active workplace initiatives, such as encouraging the use of stairs, organising short exercise breaks, and facilitating walking routes.
She added that these visual cues and practical tips are part of a larger national movement to reduce the burden of non-communicable diseases.
High obesity levels
According to a recent study published in The Lancet, nearly 45 crore Indians could be overweight or obese by 2050. This means that, by mid-century, India is likely to have the second-highest number of overweight and obese people in the world, after China.
The World Health Organisation (WHO) noted that the current food environment in which many people live, work, and spend their daily lives consists of highly processed and readily available foods high in unhealthy fats, sugars, and sodium. Many of these foods are also heavily marketed and relatively cheap. As a result, consumers are often challenged to make healthy food-related decisions. Unhealthy diets are now a leading global public health risk, contributing to noncommunicable diseases (NCDs) including obesity, diabetes, heart disease, stroke, and cancers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
34 minutes ago
- Economic Times
Of samosas, sins and the spiral of shame
Where there's pleasure, there's guilt - and the tantalising matter of guilty pleasures. So, in a grand mai-baap effort to rescue the Indian conscience from its own stomach, a new government directive is in the works that will ensure that samosas and jalebis - those golden, oily icons of joy - come branded with health warnings . The strategy is to guilt out the imbiber of the two greatest desi snacks - at least so that she or he at least goes easy on them. But by informing us of guilt, will the guilty pleasure now become more pleasurable?With every warning with a samosa, will we be nudged back into the comforting embrace of shame eating? Like Victorian England's obsession with corsets and celery sticks, we are now expected to nibble our sin-snacks with penitent faces, a gulp of guilt for every crunchy bite. The logic is simple: if smoking can be seen by smokers as 'cool' despite a warning, why not samosas? Nothing will say 'I'm a rebel' like a woman tearing into a jalebi. Soon, street vendors might shout 'Dilli-style, high cholesterol guaranteed!' to entice the hipster crowd, while aunties debate whether homemade ghee makes shame less commercial. Next up: warning labels on laddoos, followed by therapists offering post-snack guilt counselling. India, it seems, is finally eating its feelings - responsibly.
Time of India
an hour ago
- Time of India
Govt plans to upgrade 7 ICU hospitals into super specialty ones: CM Rekha Gupta
Delhi Chief Minister Rekha Gupta on Monday said the government plans to upgrade seven ICU hospitals , whose foundations were laid during the COVID-19 pandemic , into super speciality hospitals. Speaking at the inauguration of Yatharth Super Speciality Hospital in the Model Town area here, she said, "There were seven ICU hospitals whose foundations were laid during the pandemic. We have drawn up a plan for them. We will upgrade them into super speciality hospitals." "One hospital could be for cancer care, one for complicated deliveries, one for treatment of kidney ailments and dialysis," she added and urged private healthcare facilities to get empanelled in Ayushman Bharat Yojana . by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like She Was Beautiful, Now Its Hard To Look At Her Crowdy Fan Undo The CM also emphasised that there should be awareness about the distinction between primary and secondary healthcare and super speciality hospitals. "(Sometimes) it happens that if one is suffering from cough or cold, they go to AIIMS . A simple cough or cold can also be treated at Arogya Mandir," she explained.
Mint
2 hours ago
- Mint
Sacrifices, trade-offs behind big win, says Glenmark's Saldanha
The road to drug discovery is long, arduous and littered with failure, but the payoff at the end makes it worth the trouble. It's a lesson that India's best pharmaceutical entrepreneurs knew all along. Yet, it took a Glenn Saldanha to prove it. 'We were always resilient in how we approached innovation. I think that's what finally rewarded us," Saldanha, chief executive officer and managing director of Glenmark Pharmaceuticals Ltd, told Mint in an exclusive interview. He was referring to one of the largest deals for an Indian biopharma firm after Glenmark's US-based unit Ichnos Glenmark Innovation (IGI) secured a $700-million exclusive licensing agreement with AbbVie for its blood cancer drug candidate last week. AbbVie will also pay as much as $1.23 billion as various milestones are completed, as well as tiered, double-digit royalties on net sales. ISB 2001, the investigational drug to treat multiple myeloma, is in phase-1 clinical trials and has shown promising data. In a trial with 35 patients who had exhausted all existing lines of therapy unsuccessfully, 79% showed a clinical response to it, and 30% were cancer-free. 'I hope this acts as a catalyst to expanding the innovation landscape in India…we've demonstrated that you can do it," said Saldanha. Last bet ISB 2001, developed on IGI's proprietary BEAT platform, was the firm's last bet. 'There was no plan B," said Saldanha. 'This was pretty much the end of the road. At this point, the technology had to demonstrate that it worked…or we don't know what we would have done as the next thing." The drug had been in discovery over the last five years, while the company had been working on the BEAT platform for about a decade. There were three other assets that the company stopped developing. ISB 2001 has received both the US FDA Orphan Drug and Fast Track designations, highlighting its Orphan Drug designation is given to drugs treating rare diseases, while a fast track designation intends to expedite the development and review of drugs for treating serious conditions and fill unmet medical needs. Following the licensing agreement, AbbVie will take over further development for phase-2 and phase-3 trials before it can file for regulatory approval. The process would typically take four to five years. The market size for multiple myeloma is estimated to grow to $50 billion by 2030. Should the drug hit the markets in 2030, taking into account the tiered double-digit royalties, Glenmark stands to earn an additional $2.02 billion in royalties until 2041, according to research by brokerage Nuvama. The deal validates several aspects of Glenmark, including the strength of IGI's BEAT platform, the potential for ISB 2001 to treat relapsed/refractory multiple myeloma, and its commercial viability following successful clinical trials, said an 11 July note by Motilal Oswal analysts. 'Moreover, AbbVie has established itself as a diversified biopharma leader, combining scientific innovation with strong commercial execution. In oncology, the company has built a robust presence anchored by two cornerstone therapies: Imbruvica, a BTK inhibitor, and Venclexta, a BCL-2 inhibitor. These medicines have transformed the treatment landscape for chronic lymphocytic leukemia and other B-cell malignancies, generating multi-billion-dollar revenues and reinforcing AbbVie's reputation as a pioneer in hematologic cancer," the note added. Huge sacrifices, trade-offs Saldanha has bet on innovation since he took the reins of the company in the late 90s. A few years after Glenmark was listed in 2000, it established its first R&D centre for novel biologics research in Switzerland. Over the years, the company did a number of licensing deals with novel assets. In 2019, it spun off its R&D entity under a new company, Ichnos Sciences, which built on its proprietary BEAT bispecific platform. The two announced the creation of Ichnos Glenmark Innovation (IGI) in 2024. The company's focus on innovation created a lot of frustration for investors and stakeholders, Saldanha said. '[We were] bordering on being called eccentric," he said. The company also had to sell its stake in its active pharmaceutical ingredient (API) division, Glenmark Life Sciences, to pare its debt in 2023, which was approximately ₹4,500-4,600 crore. Glenmark sold 75% stake in the unit to industrial conglomerate Nirma for ₹5,650 crore. The company has made 'huge sacrifices, huge trade-offs," said Saldanha. With the GLS sale, the company had a choice to decide 'which end of the value chain we play", said Saldanha. 'Whether we play on this API stable end of the value chain, and generate revenues like that, or we play on the high end of the value chain, which is innovation." But innovation is not a cost game, he said. 'It's all about being able to understand where the therapy is going and how to come up with solutions." What's next for Glenmark? IGI spends about $70 million annually on new drug research. With the upfront payment it receives, it will be self-funded for the next three to four years, said Saldanha. The company will also look at rewarding shareholders with dividends. Apart from that, there are no immediate investment plans, said Saldanha. 'At least for the next year or two, we won't do anything. We'll just continue regrouping and trying to figure out strategically where we can further add value," he said. The deal is a big event for the company, which 'basically resets the whole agenda for the company", he said. 'We have to really reset and rethink how we want to see the company over the next five to ten years." ISB 2001's early success has validated the BEAT platform. 'We think we've now got it right with the technology…the idea is how can we exploit that technology much more effectively to add more products and do more," said Saldanha. The unit has another asset called ISB 2301, which is in late pre-clinical development and will go to the clinic next year. This drug will target solid tumours, said Saldanha. IGI also has a couple of other early-stage programs. '...over the next three, four years, we will exploit the technology as effectively as possible."
